cortisone acetate (cortone) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cortisone is a hormone that is FDA approved for the treatment of primary and secondary adrenocortical deficiency, rheumatic disorders, psoriasis, exfoliative dermatitis, bronchial asthma, allergic conjunctivitis, hemolytic anemia, enteritis, tuberculosis, trichnosis. Cortisone acetate binds to the cytosolic glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. Common adverse reactions include convulsions, increased intracranial pressure with papilledema, vertigo, headache, psychic disturbances, hirsuitism, glaucoma, exophthalmos. Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Cortisone is a natural steroid hormone. Its sulfate analog has been detected in in umbilical vein blood fetus plasma between 19 and 32 weeks of gestation with a significant increase at 29-30 weeks and in amniotic fluid. Base on the experiments with rats it was suggested that cortisone sulfate in mammals could be hydrolyzed enzymatically liberating sulfate ions from cortisone. Cortisone sulfate has been proposed for use as one of the glycosaminoglycan compound materials in a cartilage prosthesis and biological nasal bridge implant manufacture as well as auxiliary agent in powder aerosol composition for use in baby powder, dry shampoo, water-eczema remedy and antiperspirant.   NCATS

Chemistry

  • SMILES: C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
  • InChIKey: MFYSYFVPBJMHGN-ZPOLXVRWSA-N
  • Mol. Mass: 360.444
  • ALogP: 1.78
  • ChEMBL Molecules:
    cortisone  
    cortisone  
    cortisone acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.1137 - $0.1610
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

adrenalex | cortelan | cortisone | cortisone acetate | cortistab | cortisyl | cortone | cortone acetate | irisone acetate

Organizations (46)

Research & Development (29)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (3)


 

Addison Disease (approved 1955)

Hypersensitivity (approved 1955)

Rheumatic Diseases (approved 1955)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Adrenal Hyperplasia, Congenital (Phase 4)

Angioedema (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Hip Injuries (Phase 4)

Low Back Pain (Phase 3)

Obesity (Phase 1)

Osteoarthritis (Phase 2/Phase 3)

Osteoarthritis, Knee (Phase 1)

Out-of-Hospital Cardiac Arrest (Phase 2)

Post-Cardiac Arrest Syndrome (Phase 2)

Rheumatic Diseases (Phase 4)

Rotator Cuff Injuries (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 29

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue